Spyryx Biosciences is a biopharmaceutical company developing inhaled therapeutics for severe respiratory diseases, with Cystic Fibrosis (CF) as the first target indication. Our development efforts are based on novel peptides that reduce the airway surface density of epithelial sodium channels (ENaC) via ligand-mediated internalization. This mechanism has a robust and durable effect on enhancing airway and mucus hydration to promote mucociliary clearance. We believe the mechanism of our investigational peptides has the potential to provide disease-modification for the dehydration associated lung disease that is a feature of CF, as well as having utility in multiple other pulmonary and non-pulmonary indications. Spyryx’s lead program, SPX-101, has successfully completed a Phase 1 safety study in healthy volunteers and is now being tested in a multinational Phase 2 study in individuals living with CF. The Phase 2, entitled "Hydration for Optimal Pulmonary Effectiveness" or HOPE-1, is a 28-day, placebo-controlled study intended to establish treatment proof of concept independent of CFTR mutation (www.clinicaltrials.gov/NCT03229252). This study has initiated recruitment in select sites in Canada and Western Europe. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.
View Top Employees from SPYRYX BiosciencesWebsite | http://www.spyryxbio.com |
Revenue | $6.3 million |
Employees | 5 (1 on RocketReach) |
Founded | 2013 |
Address | 801-10 Capitola Drive, Durham, North Carolina 27713, US |
Phone | (919) 899-9399 |
Technologies | |
Industry | Biotechnology, Business Services General, Genetics, Pharmaceuticals, Respiratory Therapeutics, Business Services, Drug Discovery, Chronic Obstructive Pulmonary Disease (COPD), Health Care, Cystic Fibrosis, Health Diagnostics, Therapeutics |
Web Rank | 16 Million |
Keywords | Spyryx Biosciences Inc, Spyryx Pharmaceuticals |
Competitors | Applied Therapeutics Inc, CohBar, Inc., Ember Therapeutics, Moerae Matrix, Inc., Trevi Therapeutics, Inc. |
SIC | SIC Code 283 Companies, SIC Code 80 Companies, SIC Code 28 Companies, SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541711 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies |
Looking for a particular SPYRYX Biosciences employee's phone or email?
The SPYRYX Biosciences annual revenue was $6.3 million in 2024.
1 people are employed at SPYRYX Biosciences.
SPYRYX Biosciences is based in Durham, North Carolina.
The NAICS codes for SPYRYX Biosciences are [54, 541711, 5417, 54171, 541].
The SIC codes for SPYRYX Biosciences are [283, 80, 28, 87, 873].